Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma

Ann Hematol. 2018 Aug;97(8):1489-1491. doi: 10.1007/s00277-018-3279-8. Epub 2018 Feb 17.

Authors

Tomonori Nakazato¹, Satoshi Takanashi^{2

3}, Motoharu Hirano³, Chisako Ito², Yuriko Fujita², Yuki Osada², Yoshinobu Aisa², Takehiko Mori⁴

Affiliations

¹ Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan. n-tomo@eurus.dti.ne.jp.
² Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan.
³ Department of Rheumatology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
⁴ Division of Hematology, Keio University School of Medicine, Tokyo, Japan.

PMID: 29455236
DOI: 10.1007/s00277-018-3279-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Arthritis, Rheumatoid* / diagnosis
Arthritis, Rheumatoid* / drug therapy
Arthritis, Rheumatoid* / pathology
Brentuximab Vedotin
Female
Hodgkin Disease* / chemically induced
Hodgkin Disease* / diagnosis
Hodgkin Disease* / drug therapy
Hodgkin Disease* / pathology
Humans
Immunoconjugates / administration & dosage*
Methotrexate / administration & dosage
Methotrexate / adverse effects*
Middle Aged

Substances

Immunoconjugates
Brentuximab Vedotin
Methotrexate